Education

Undergraduate School

Barnard College, Columbia University
1994 New York NY

Medical School

Harvard Medical School
2000 Boston MA

Internship

Medicine Boston Children's Hospital
2001 Boston MA

Residency

Pediatrics Boston Combined Residency Program (BCRP)
2003 Boston MA

Fellowship

Pediatric Hematology-Oncology Boston Children's Hospital and Dana-Farber Cancer Institute
2007 Boston MA

Graduate School

MMSc Harvard Medical School
2008 Boston MA

Publications

  1. SMARCAL1 is a new osteosarcoma predisposition gene. J Natl Cancer Inst. 2026 Jun 01; 118(6):1120-1125. View Abstract
  2. Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study. JCO Precis Oncol. 2026 May; 10(5):e2501125. View Abstract
  3. An international framework for clinical translation of molecular classifiers in osteosarcoma. NPJ Precis Oncol. 2026 May 05. View Abstract
  4. Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium. Clin Cancer Res. 2026 Mar 02; 32(5):831-834. View Abstract
  5. Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical Trial. JAMA Netw Open. 2026 Mar 02; 9(3):e263666. View Abstract
  6. Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk. medRxiv. 2026 Feb 09. View Abstract
  7. Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults. J Natl Cancer Inst. 2026 Feb 01; 118(2):199-204. View Abstract
  8. Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies. Commun Med (Lond). 2026 Jan 23; 6(1):88. View Abstract
  9. A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):36-44. View Abstract
  10. Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2026 Jun 01; 125(2):521-529. View Abstract
  11. MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma. Cancer. 2025 Nov 15; 131(22):e70161. View Abstract
  12. Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2025 12 10; 43(35):3750-3759. View Abstract
  13. Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2025 Oct; 9:e2500742. View Abstract
  14. PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study. JCO Oncol Adv. 2025; 2. View Abstract
  15. Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. J Natl Cancer Inst. 2025 Sep 01; 117(9):1764-1773. View Abstract
  16. Supporting Participant Engagement in Cancer Genomics Research in Rare Cancers: A Qualitative Study of Patients, Caregivers, and Advocates. Cancer Control. 2025 Jan-Dec; 32:10732748251364041. View Abstract
  17. Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations. J Mol Diagn. 2025 Oct; 27(10):969-988. View Abstract
  18. Optimizing participant and community engagement in cancer genomic sequencing research. Genet Med. 2025 Sep; 27(9):101483. View Abstract
  19. Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Aug; 72(8):e31820. View Abstract
  20. Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. medRxiv. 2025 Jan 20. View Abstract
  21. Rare germline structural variants increase risk for pediatric solid tumors. Science. 2025 01 03; 387(6729):eadq0071. View Abstract
  22. Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. J Natl Compr Canc Netw. 2024 12 27; 23(1). View Abstract
  23. Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2024 12 01; 10(12):1645-1653. View Abstract
  24. Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report. J Natl Cancer Inst. 2024 Oct 01; 116(10):1664-1674. View Abstract
  25. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258. View Abstract
  26. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418. View Abstract
  27. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract
  28. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 08 05; 29(8):723-e1093. View Abstract
  29. Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality. J Clin Oncol. 2024 Dec; 42(34):4018-4022. View Abstract
  30. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. Eur J Cancer. 2024 Sep; 208:114229. View Abstract
  31. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract
  32. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 07 05; 29(7):638-e952. View Abstract
  33. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103. View Abstract
  34. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894. View Abstract
  35. Innovations in Cancer Treatment of Children. Pediatrics. 2023 12 01; 152(6). View Abstract
  36. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363. View Abstract
  37. Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials. Pediatr Blood Cancer. 2023 12; 70(12):e30662. View Abstract
  38. Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatr Blood Cancer. 2023 Dec; 70(12):e30681. View Abstract
  39. Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. JCO Clin Cancer Inform. 2023 09; 7:e2300104. View Abstract
  40. Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. J Clin Oncol. 2023 10 20; 41(30):4724-4728. View Abstract
  41. Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30652. View Abstract
  42. Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30643. View Abstract
  43. Children's Oncology Group's 2023 blueprint for research: Bone tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30583. View Abstract
  44. A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials. Pediatr Blood Cancer. 2023 Jun 27; e30506. View Abstract
  45. The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. J Clin Oncol. 2023 08 20; 41(24):4045-4053. View Abstract
  46. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract
  47. Clear cell tumor with melanocytic differentiation and MITF::CREM translocation. J Cutan Pathol. 2023 Jul; 50(7):619-622. View Abstract
  48. Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Cancer Epidemiol Biomarkers Prev. 2023 04 03; 32(4):487-495. View Abstract
  49. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. Pediatr Blood Cancer. 2023 06; 70(6):e30262. View Abstract
  50. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334. View Abstract
  51. Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. J Adolesc Young Adult Oncol. 2023 Oct; 12(5):792-793. View Abstract
  52. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 04 10; 41(11):2098-2107. View Abstract
  53. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8(1):82. View Abstract
  54. Osteosarcoma. Nat Rev Dis Primers. 2022 12 08; 8(1):77. View Abstract
  55. Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235]. Eur J Cancer. 2022 Dec; 177:208-209. View Abstract
  56. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. View Abstract
  57. Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2023 02 01; 115(2):337-346. View Abstract
  58. Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. Br J Cancer. 2022 12; 127(12):2220-2226. View Abstract
  59. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6(1):65. View Abstract
  60. Comment on: Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents: ROS1-fusion inflammatory myofibroblastic tumor: ROS1-fusion inflammatory myofibroblastic tumor. Pediatr Blood Cancer. 2023 02; 70(2):e29907. View Abstract
  61. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 09; 173:71-90. View Abstract
  62. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. Eur J Cancer. 2022 Sep; 172:264-275. View Abstract
  63. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View Abstract
  64. Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma. Eur J Cancer. 2022 07; 170:209-235. View Abstract
  65. Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. JCO Precis Oncol. 2022 06; 6:e2200099. View Abstract
  66. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. Histopathology. 2022 Aug; 81(2):215-227. View Abstract
  67. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am J Hum Genet. 2022 06 02; 109(6):1026-1037. View Abstract
  68. 68 Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. Pediatr Blood Cancer. 2022 08; 69(8):e29740. View Abstract
  69. BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. Cancer Res Commun. 2022 04; 2(4):220-232. View Abstract
  70. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245. View Abstract
  71. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234. View Abstract
  72. Rapid and highly sensitive approach for multiplexed somatic fusion detection. Mod Pathol. 2022 08; 35(8):1022-1033. View Abstract
  73. Reply to J.-G. Wang et al. J Clin Oncol. 2022 05 01; 40(13):1507-1508. View Abstract
  74. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. View Abstract
  75. Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Arch Pathol Lab Med. 2021 12 01; 145(12):1564-1568. View Abstract
  76. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. Pediatrics. 2021 12 01; 148(6). View Abstract
  77. Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 11 25; 385(22):2059-2065. View Abstract
  78. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 12 20; 39(36):4029-4038. View Abstract
  79. Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. J Adolesc Young Adult Oncol. 2022 06; 11(3):328-332. View Abstract
  80. Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29333. View Abstract
  81. Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clin Cancer Inform. 2021 09; 5:1034-1043. View Abstract
  82. Assessment of BCOR Internal Tandem Duplications in Pediatric Cancers by Targeted RNA Sequencing. J Mol Diagn. 2021 10; 23(10):1269-1278. View Abstract
  83. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 09; 68(9):e29188. View Abstract
  84. Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. Cancer Res. 2021 08 01; 81(15):3971-3984. View Abstract
  85. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Apr; 10(7):2310-2318. View Abstract
  86. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439. View Abstract
  87. OncoTree: A Cancer Classification System for Precision Oncology. JCO Clin Cancer Inform. 2021 02; 5:221-230. View Abstract
  88. Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2021 05; 87(5):621-634. View Abstract
  89. A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. Pediatr Blood Cancer. 2021 04; 68(4):e28780. View Abstract
  90. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma. 2020; 2020:3498549. View Abstract
  91. Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. Pediatr Blood Cancer. 2021 03; 68(3):e28834. View Abstract
  92. Desmoid tumors of the head and neck in the pediatric population: Has anything changed? Int J Pediatr Otorhinolaryngol. 2021 Jan; 140:110511. View Abstract
  93. PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate? J Pediatr Hematol Oncol. 2020 11; 42(8):482-487. View Abstract
  94. Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. JCO Precis Oncol. 2020 Nov; 4:1084-1097. View Abstract
  95. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1267-1273. View Abstract
  96. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases. Pediatr Blood Cancer. 2020 10; 67(10):e28636. View Abstract
  97. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract
  98. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View Abstract
  99. Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology. 2020 Jun; 76(7):1032-1041. View Abstract
  100. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View Abstract
  101. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View Abstract
  102. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. J Natl Cancer Inst. 2020 03 01; 112(3):224-228. View Abstract
  103. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 04 15; 26(8):1837-1845. View Abstract
  104. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View Abstract
  105. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. Cardiooncology. 2019; 5:15. View Abstract
  106. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist. 2020 01; 25(1):e39-e47. View Abstract
  107. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer. 2019 11; 121:177-183. View Abstract
  108. A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. Int J Surg Pathol. 2020 Apr; 28(2):128-137. View Abstract
  109. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019 12 01; 37(34):3192-3202. View Abstract
  110. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 10 15; 125(20):3514-3525. View Abstract
  111. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun Biol. 2019; 2:266. View Abstract
  112. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun Biol. 2019 Jul 19; 2(1):266. View Abstract
  113. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. Cancer Chemother Pharmacol. 2019 07; 84(1):41-50. View Abstract
  114. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019; 8. View Abstract
  115. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. View Abstract
  116. Ushering in the next generation of precision trials for pediatric cancer. Science. 2019 Mar 15; 363(6432):1175-1181. View Abstract
  117. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract
  118. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 03; 109:36-50. View Abstract
  119. Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. JCO Precis Oncol. 2019; 3. View Abstract
  120. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clin Cancer Res. 2019 02 15; 25(4):1343-1357. View Abstract
  121. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 02; 66(2):e27524. View Abstract
  122. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 01; 66(1):e27444. View Abstract
  123. Dose Intensification Improves the Outcome of Ewing Sarcoma. J Clin Oncol. 2018 Sep 12; JCO2018793489. View Abstract
  124. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. View Abstract
  125. Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964. View Abstract
  126. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018; 2018. View Abstract
  127. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. View Abstract
  128. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018 02; 30(1):17-24. View Abstract
  129. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 2018 04; 65(4). View Abstract
  130. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 03; 31(3):463-473. View Abstract
  131. Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1286-1294. View Abstract
  132. Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS One. 2017; 12(7):e0181204. View Abstract
  133. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Abstract
  134. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e68-e75. View Abstract
  135. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017 06 01; 23(11):e38-e45. View Abstract
  136. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 2017 05 15; 10(1):107. View Abstract
  137. Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer. 2017 Sep 15; 123(18):3434-3440. View Abstract
  138. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5). View Abstract
  139. Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact. Pediatr Blood Cancer. 2017 06; 64(6). View Abstract
  140. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200. View Abstract
  141. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res. 2017 01 15; 77(2):509-519. View Abstract
  142. Advances in the Treatment of Pediatric Bone Sarcomas. Am Soc Clin Oncol Educ Book. 2017; 37:725-735. View Abstract
  143. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017 Feb 10; 35(5):523-528. View Abstract
  144. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatr Blood Cancer. 2017 Jul; 64(7). View Abstract
  145. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View Abstract
  146. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct; 17(10):1396-1408. View Abstract
  147. The case for informative phase 2 trials in osteosarcoma. Lancet Oncol. 2016 08; 17(8):1022-1023. View Abstract
  148. Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Ann Surg Oncol. 2016 12; 23(Suppl 5):990-997. View Abstract
  149. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016 11; 63(11):1974-82. View Abstract
  150. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8. View Abstract
  151. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. F1000Res. 2016; 5. View Abstract
  152. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016 Jul 01; 2(7):922-8. View Abstract
  153. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987. View Abstract
  154. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract
  155. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016 10; 63(10):1737-43. View Abstract
  156. Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016 05; 209(5):182-94. View Abstract
  157. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 07 15; 22(14):3643-50. View Abstract
  158. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016 Feb; 28(1):26-33. View Abstract
  159. Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. J Surg Oncol. 2016 Mar; 113(4):351-4. View Abstract
  160. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000471. View Abstract
  161. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Feb; 63(2):370-1. View Abstract
  162. Integrity of the pheochromocytoma susceptibility TMEM127 gene in patients with pediatric malignancies. Endocr Relat Cancer. 2015 Jun; 22(3):L5-7. View Abstract
  163. Marketing of personalized cancer care on the web: an analysis of Internet websites. J Natl Cancer Inst. 2015 May; 107(5). View Abstract
  164. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73. View Abstract
  165. A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer. 2015 Mar; 62(3):450-5. View Abstract
  166. Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. Fam Cancer. 2014 Sep; 13(3):507-11. View Abstract
  167. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014 Aug 15; 20(16):4200-9. View Abstract
  168. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer. 2014 Sep; 61(9):1558-64. View Abstract
  169. Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. PLoS One. 2013; 8(5):e64102. View Abstract
  170. Future of clinical genomics in pediatric oncology. J Clin Oncol. 2013 May 20; 31(15):1893-903. View Abstract
  171. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013 Jun; 3(6):648-57. View Abstract
  172. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013; 5(1):2. View Abstract
  173. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013 Jun; 60(6):1009-15. View Abstract
  174. New strategies in sarcoma therapy: linking biology and novel agents. Clin Cancer Res. 2012 Nov 01; 18(21):5837-44. View Abstract
  175. Treatment guidelines for gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol. 2012 May; 34 Suppl 2:S69-72. View Abstract
  176. Cardiac paraganglioma in an adolescent. Circulation. 2012 Feb 07; 125(5):e322-4. View Abstract
  177. Pediatric gastrointestinal stromal tumor. Semin Pediatr Surg. 2012 Feb; 21(1):31-43. View Abstract
  178. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012 Sep 15; 118(18):4597-605. View Abstract
  179. Special considerations in pediatric gastrointestinal tumors. J Surg Oncol. 2011 Dec; 104(8):928-32. View Abstract
  180. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011 Apr 01; 71(7):2686-96. View Abstract
  181. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer. 2012 Feb; 58(2):181-4. View Abstract
  182. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):314-8. View Abstract
  183. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010 Dec 01; 127(11):2718-22. View Abstract
  184. Modeling human osteosarcoma in the mouse: From bedside to bench. Bone. 2010 Nov; 47(5):859-65. View Abstract
  185. Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. Curr Opin Oncol. 2010 Jul; 22(4):347-50. View Abstract
  186. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010 Jul; 11(7):670-8. View Abstract
  187. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71. View Abstract
  188. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009 Feb; 23(1):15-34, vii. View Abstract
  189. Pediatric GIST. Hematology Oncology Clinics of North America. 2009; 23(1). View Abstract
  190. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007 Oct 01; 67(19):9084-8. View Abstract
  191. Neutropenia. Comprehensive Pediatric Hospital Medicine (Zaoutis LB and Chiang VW eds.). 2007; 738-743. View Abstract
  192. Successful treatment of pediatric metastatic gastrointestinal stromal tumor (GIST) with Sunitinib after failure of imatinib. Journal of Clinical Oncology. 2006; 24(18s):9519. View Abstract
  193. Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9519. View Abstract
  194. Fever without a source in infants and young children. Boston Combined Residency Program Pediatric Guidebook (Binstadt B and Gupta M eds.). 2001. View Abstract
  195. Carpal tunnel syndrome and workers' compensation among an occupational clinic population in New York State. Am J Ind Med. 1999 Apr; 35(4):335-42. View Abstract

Contact Katherine Janeway

Print Profile